Adma Biologics Inc (NASDAQ: ADMA) on Friday, plunged -0.43% from the previous trading day, before settling in for the closing price of $18.67. Within the past 52 weeks, ADMA’s price has moved between $3.73 and $23.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 73.26%. The company achieved an average annual earnings per share of 496.15%. With a float of $228.48 million, this company’s outstanding shares have now reached $236.38 million.
Considering the fact that the conglomerate employs 624 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 48.79%, operating margin of 30.01%, and the pretax margin is 19.16%.
Adma Biologics Inc (ADMA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adma Biologics Inc is 3.35%, while institutional ownership is 88.43%. The most recent insider transaction that took place on Nov 22 ’24, was worth 317,250. In this transaction CFO and Treasurer of this company sold 15,000 shares at a rate of $21.15, taking the stock ownership to the 199,433 shares. Before that another transaction happened on Nov 22 ’24, when Company’s President and CEO sold 48,967 for $21.10, making the entire transaction worth $1,033,204. This insider now owns 1,989,007 shares in total.
Adma Biologics Inc (ADMA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 496.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.00% during the next five years compared to 38.68% growth over the previous five years of trading.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Adma Biologics Inc (ADMA) is currently performing well based on its current performance indicators. A quick ratio of 3.26 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.43. Likewise, its price to free cash flow for the trailing twelve months is 55.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.28, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.74 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Compared to the last year’s volume of 3.58 million, its volume of 2.39 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 22.48%. Additionally, its Average True Range was 0.95.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 62.40%, which indicates a significant increase from 7.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.22% in the past 14 days, which was lower than the 79.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.99, while its 200-day Moving Average is $13.28. Nevertheless, the first resistance level for the watch stands at $19.02 in the near term. At $19.44, the stock is likely to face the second major resistance level. The third major resistance level sits at $19.81. If the price goes on to break the first support level at $18.23, it is likely to go to the next support level at $17.86. Now, if the price goes above the second support level, the third support stands at $17.44.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
Market capitalization of the company is 4.38 billion based on 236,390K outstanding shares. Right now, sales total 258,220 K and income totals -28,240 K. The company made 119,840 K in profit during its latest quarter, and 35,910 K in sales during its previous quarter.
